Long-Term Survival Following Cytoreductive Surgery and HIPEC for Pseudomyxoma Peritonei: Insights from a 22-Year Single Institution Experience and Contemporary Evidence Synthesis
Comprehensive 22-year singular institutional data affirm CRS and HIPEC yield promising long-term survival for PMP, with 62% 5-year overall survival.
Histopathological grade, completeness of cytoreduction (CC0-1), and tumor markers such as CEA significantly influence prognosis.
Recent studies favor cisplatin plus docetaxel HIPEC regimens, urine-guided intraoperative hydration reduces AKI risk, and perioperative nutritional support enhances recovery.
Nomograms and prognostic classifications (PSOGI) improve individual patient risk stratification and clinical decision-making.
